Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor marketed under brand names including Farxiga​ and Xigduo XR, has revolutionized the treatment landscape for type 2 diabetes, heart failure, and chronic kidney disease. As a blockbuster drug with expanding therapeutic indications, dapagliflozin represents a critical component of global pharmaceutical procurement strategies. The global market for SGLT2 inhibitors including dapagliflozin was valued at USD 7.8 billion in 2024​ and is projected to reach USD 12.8 billion by 2030, growing at a CAGR of 8.6% . This growth is driven by robust clinical evidence supporting cardiovascular and renal benefits beyond glycemic control, leading to expanded reimbursement and formulary inclusion worldwide. Understanding the complex global buyer…